Thomas Bachelot

Thomas Bachelot

UNVERIFIED PROFILE

Are you Thomas Bachelot?   Register this Author

Register author
Thomas Bachelot

Thomas Bachelot

Publications by authors named "Thomas Bachelot"

Are you Thomas Bachelot?   Register this Author

100Publications

4817Reads

20Profile Views

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.

J Clin Oncol 2018 04 22;36(10):981-990. Epub 2018 Feb 22.

Dimitrios Zardavas and Debora Fumagalli, Breast International Group; Christos Sotiriou, Université Libre de Bruxelles, Brussels, Belgium; Luc te Marvelde and Roger L. Milne, Cancer Council; Roger L. Milne and Sherene Loi, University of Melbourne, Melbourne; Barry Iacopetta, University of Western Australia, Western Australia; Sandra O'Toole and Elena Lopez-Knowles, Garvan Institute of Medical Research, Darlinghurst, Australia; George Fountzilas and Vassiliki Kotoula, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki; Evangelia Razis, Hygeia Hospital; George Papaxoinis, Hippokration Hospital, Athens, Greece; Heikki Joensuu, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Mary Ellen Moynahan, Memorial Sloan Kettering Cancer Center, New York, NY; Bryan T. Hennessy, Beaumont Hospital and Royal College of Surgeons, Dublin, Ireland; Ivan Bieche, Curie Institut, Paris; Thomas Bachelot, Centre de Recherche en Cancérologie de Lyon, Lyon; Stefan Michiels, Gustave Roussy and Inserm, Univ. Paris-Sud, Univ. Paris-Saclay, Villejuif, France; Lao H. Saal, Lund University, Lund; Olle Stal, Qing Wang, and Gizeh Perez-Tenorio, Linköping University, Linköping, Sweden; Jeanette Dupont Jensen, University of Southern Denmark, on behalf of the Danish Breast Cancer Cooperative Group, Odense, Denmark; Elena Lopez-Knowles, Royal Marsden NHS Trust and Institute of Cancer Research, London; Daniel W. Rea, University of Birmingham, Birmingham, United Kingdom; Mattia Barbaraeschi, Santa Chiara Hospital, Trento, Italy; Shinzaburo Noguchi, Osaka University, Osaka Japan; Hatem A. Azim Jr, American University of Beirut (AUB), Beirut, Lebanon; Enrique Lerma, Universitat Autònoma de Barcelona, Barcelona, Spain; Cornelis J.H. can de Velde, Leiden University Medical Center, Leiden, the Netherlands; Vicky Sabine, University of Guelph, Guelph; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.8301DOI Listing
April 2018

Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.

Breast Cancer 2018 Jan 16;25(1):17-27. Epub 2017 Nov 16.

Medical Oncology Department, Centre Leon Berard, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-017-0818-4DOI Listing
January 2018

The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials.

Eur J Cancer 2017 04 24;75:245-258. Epub 2017 Feb 24.

Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129 Trieste, Italy; Unit of Molecular Therapy and Pharmacogenomic, ASST Cremona, Viale Concordia 1, 26100 Cremona, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.01.026DOI Listing
April 2017

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

N Engl J Med 2016 11 7;375(18):1738-1748. Epub 2016 Oct 7.

From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1609709DOI Listing
November 2016

PI3K targeting in breast cancer: the end of the beginning?

Lancet Oncol 2016 06 4;17(6):696-697. Epub 2016 May 4.

Centre Léon Bérard, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)00148-0DOI Listing
June 2016

Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.

Breast Cancer Res Treat 2016 06 11;157(2):307-318. Epub 2016 May 11.

Medical Oncology Department, Institut Claudius Regaud, IUCT-Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-3828-6DOI Listing
June 2016

[Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases].

Bull Cancer 2016 May 15;103(5):507-10. Epub 2016 Mar 15.

Centre Léon-Bérard, département d'oncologie médicale, 69008 Lyon, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2016.02.005DOI Listing
May 2016

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

J Clin Oncol 2016 Feb 26;34(5):419-26. Epub 2015 Oct 26.

Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; David Chen, Tetiana Taran, and David Lebwohl, Novartis Pharmaceuticals, East Hanover, NJ; Martine Piccart and Fabienne Lebrun, Université Libre de Bruxelles, Brussels; Ines Deleu, Oncology Centre, AZ Nikolaas, Sint-Nikolaas, Belgium; Hope S. Rugo, University of California, San Francisco; Ian Anderson, Redwood Regional Oncology Center, Santa Rosa, CA; Howard A. Burris III, Sarah Cannon Research Institute, Nashville, TN; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, Ontario, Canada; Mario Campone, Centre de Recherche en Cancerologie, Nantes-Saint-Herblain; Thomas Bachelot, Centre Léon Bérard, Lyon, France; Shinzaburo Noguchi, Osaka University Medical School; Norikazu Masuda, Osaka National Hospital, Osaka, Japan; Alejandra T. Perez, Memorial Cancer Institute, Hollywood, FL; Mikhail Shtivelband, Ironwood Cancer & Research Centers, Chandler, AZ; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Douglas M. Robinson, Wei He, Abhishek Garg, E. Robert McDonald III, Hans Bitter, and Alan Huang, Novartis Institutes for BioMedical Research, Cambridge, MA; and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.1971DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070556PMC
February 2016

Pharmacokinetic interaction between pazopanib and cisplatin regimen.

Cancer Chemother Pharmacol 2016 Feb 16;77(2):385-92. Epub 2016 Jan 16.

Institut Claudius-Regaud, IUCT-O, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2953-yDOI Listing
February 2016

[Quinze questions importantes à se poser en oncologie en 2015].

Bull Cancer 2015 Jun;102(6 Suppl 1):S22-6

Centre Léon-Berard, & Cancer Research Center of Lyon 28, rue Laennec, 69008 Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0007-4551(15)31214-5DOI Listing
June 2015

[Advanced luminal breast cancer (hormone receptor-positive, HER2 negative): New therapeutic options in 2015].

Bull Cancer 2015 Jun;102(6 Suppl 1):S47-52

Département de médecine, Centre Léon-Bérard, Lyon, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0007-4551(15)31217-0DOI Listing
June 2015

[New therapeutical strategies in metastatic hormone-dependent breast cancer].

Bull Cancer 2015 Apr 21;102(4):367-80. Epub 2015 Mar 21.

Centre Léon-Bérard, 69008 Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2015.02.013DOI Listing
April 2015

Therogenetics: transferring GWAS technology to the clinic.

Mutagenesis 2015 Mar;30(2):213-5

Université de Lyon, F-69000 Lyon, France, Université Lyon 1, F-69100 Villeurbanne, France, INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, F-69000 Lyon, France and Centre Léon Bérard, F-69008 Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/mutage/geu060DOI Listing
March 2015

A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.

Cancer Treat Rev 2015 Feb 30;41(2):94-104. Epub 2014 Dec 30.

Royal Melbourne Hospital, Grattan St., Parkville, Melbourne 3050, Australia. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03057372140021
Publisher Site
http://dx.doi.org/10.1016/j.ctrv.2014.12.011DOI Listing
February 2015

A functional interplay between ZNF217 and estrogen receptor alpha exists in luminal breast cancers.

Mol Oncol 2014 Dec 10;8(8):1441-57. Epub 2014 Jun 10.

ISPB, Faculté de Pharmacie, Lyon, France; Université Lyon 1, Lyon, France; INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2014.05.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528595PMC
December 2014

LKB1 when associated with methylatedERα is a marker of bad prognosis in breast cancer.

Int J Cancer 2014 Sep 4;135(6):1307-18. Epub 2014 Mar 4.

Université de Lyon, France; Université Lyon 1, France; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, France; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, France; Equipe Labellisée "La Ligue", Lyon, France.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ijc.28781
Publisher Site
http://dx.doi.org/10.1002/ijc.28781DOI Listing
September 2014

The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.

Target Oncol 2014 Jun 14;9(2):111-22. Epub 2013 Jul 14.

Department of Clinical Research, Institut Curie, Paris, France,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-013-0287-4DOI Listing
June 2014

A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer.

Cancer Lett 2014 Feb 14;343(1):33-41. Epub 2013 Sep 14.

Université de Lyon, Centre Léon Bérard, Département d'Oncologie Médicale, 28 rue Laennec, 69008 Lyon, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2013.09.011DOI Listing
February 2014

mTOR inhibitors in advanced breast cancer: ready for prime time?

Cancer Treat Rev 2013 Nov 1;39(7):742-52. Epub 2013 Apr 1.

Breakthrough Breast Cancer Centre, Institute of Cancer Research, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2013.02.005DOI Listing
November 2013

Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.

Clin Cancer Res 2013 Jul 8;19(13):3693-702. Epub 2013 May 8.

Department of Medical Oncology, INSERM Unit U981, Paris Sud University, Institut Gustave-Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0190DOI Listing
July 2013

Targeted treatments for breast cancer: a step forward.

Lancet Oncol 2013 May 18;14(6):438-9. Epub 2013 Apr 18.

Departement de Cancerologie Medicale, Centre de Recherche en, Cancerologie de Lyon, Centre Leon Berard, 69373 Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(13)70153-0DOI Listing
May 2013

Reply to J.-H. Choi et al.

J Clin Oncol 2013 Feb;31(4):511

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.46.7399DOI Listing
February 2013

[Tumor resistance to HER2 inhibitors: the drug sedimentation concept].

Bull Cancer 2012 Jun;99(6):665-72

Centre René-Gauducheau, département d'oncologie médicale, boulevard Jacques-Monod, 44805 Saint-Herblain, Nantes Cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2012.1591DOI Listing
June 2012

Physicians' preferences for prescribing oral and intravenous anticancer drugs: a Discrete Choice Experiment.

Eur J Cancer 2012 Apr 25;48(6):912-20. Epub 2011 Oct 25.

Epidémiologie, Évaluation et Politiques de Santé (EA4069), Université Paris Descartes, Sorbonne Paris Cité, 1 place du parvis de Notre Dame, 75181 Paris Cedex 04, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2011.09.019DOI Listing
April 2012

A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.

Breast Cancer Res Treat 2012 Jan 24;131(1):127-35. Epub 2011 Sep 24.

Centre Catherine de Sienne, 2 Rue Eric Tabarly, BP 20215, 44202 Nantes Cedex 2, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-011-1776-8DOI Listing
January 2012

[Antihormonal therapy in breast cancer and mTOR inhibitors].

Bull Cancer 2011 Dec;98(12):1431-7

Centre Léon-Bérard, oncologie médicale, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2011.1496DOI Listing
December 2011